UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination

Nature medicine, 2022-03, Vol.28 (3), p.486-489

2022

Volltextzugriff (PDF)

Cross‐Reactive Antibody Responses to Coronaviruses Elicited by SARS‐CoV‐2 Infection or Vaccination

Influenza and other respiratory viruses, 2024-05, Vol.18 (5), p.e13309-n/a

2024

Volltextzugriff (PDF)

Immunogenicity against wild-type and Omicron SARS-CoV-2 after a third dose of inactivated COVID-19 vaccine in healthy adolescents

Frontiers in immunology, 2023-03, Vol.14, p.1106837

2023

Volltextzugriff (PDF)

Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine

Clinical infectious diseases, 2023-02, Vol.76 (3), p.e299-e307

2023

Volltextzugriff (PDF)

Author Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents

Nature communications, 2022-08, Vol.13 (1), p.4798-4798, Article 4798

2022

Volltextzugriff (PDF)

Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection

EClinicalMedicine, 2021-11, Vol.41, p.101174-101174, Article 101174

2021

Volltextzugriff (PDF)

Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents

Nature communications, 2022-06, Vol.13 (1), p.3700-15, Article 3700

2022

Volltextzugriff (PDF)

Durability for 12 months of antibody response to a booster dose of monovalent BNT162b2 in adults who had initially received 2 doses of inactivated vaccine

Vaccine, 2024-12, Vol.42 (26), p.126317, Article 126317

2024

Volltextzugriff (PDF)

Natural Reassortment of Eurasian Avian-like Swine H1N1 and Avian H9N2 Influenza Viruses in Pigs, China

Emerging infectious diseases, 2022-07, Vol.28 (7), p.1509-1512

2022

Volltextzugriff (PDF)

Slow Waning of Antibodies Following BNT162b2 as a Third Dose in Adults Who Had Previously Received 2 Doses of Inactivated Vaccine

The Journal of infectious diseases, 2023-01, Vol.227 (2), p.251-255

2023

Volltextzugriff (PDF)

Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection

Journal of clinical virology, 2022-11, Vol.156, p.105273-105273, Article 105273

2022

Volltextzugriff (PDF)

Superior antibody and membrane protein-specific T-cell responses to CoronaVac by intradermal versus intramuscular routes in adolescents

World journal of pediatrics : WJP, 2024-04, Vol.20 (4), p.353-370

2024

Volltextzugriff (PDF)

Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after third-dose BNT162b2 in adolescents

Signal transduction and targeted therapy, 2022-12, Vol.7 (1), p.397-397, Article 397

2022

Volltextzugriff (PDF)

Slow waning of antibodies following a third dose of BNT162b2 in adults who had previously received two doses of inactivated vaccine

The Journal of infectious diseases, 2022-09

2022

Volltextzugriff (PDF)

Immunogenicity of a third dose of BNT162b2 to ancestral SARS-CoV-2 & Omicron variant in adults who received two doses of inactivated vaccine

Clinical infectious diseases, 2022-06

2022

Volltextzugriff (PDF)

Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination

Virology journal, 2024-03, Vol.21 (1), p.70-70, Article 70

2024

Volltextzugriff (PDF)

Neutralizing antibodies against the SARS-CoV-2 Omicron BA.1 variant following homologous and heterologous CoronaVac or BNT162b2 vaccination

Nature medicine, 2022-01, Vol.28 (3), p.486-489

2022

Volltextzugriff (PDF)

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

Leukemia, 2022-07, Vol.36 (7), p.1720-1748

2022

Volltextzugriff (PDF)

Security analysts and capital market anomalies

Journal of financial economics, 2020-07, Vol.137 (1), p.204-230

2020

Volltextzugriff (PDF)

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

Leukemia, 2022-07, Vol.36 (7), p.1703-1719

2022

Volltextzugriff (PDF)

Magnetic augmentation through multi-gradient coupling enables direct and programmable profiling of circulating biomarkers

Nature communications, 2024-09, Vol.15 (1), p.8410-14, Article 8410

2024

Volltextzugriff (PDF)

Replicating and Digesting Anomalies in the Chinese A-Share Market

Management science, 2024-08, Vol.70 (8), p.5066-5090

2024

Volltextzugriff (PDF)

Randomized, placebo-controlled, double-blind, pilot trial to investigate safety and efficacy of Cerebrolysin in patients with aneurysmal subarachnoid hemorrhage

BMC neurology, 2020-11, Vol.20 (1), p.401-401, Article 401

2020

Volltextzugriff (PDF)

Triple‐threat quantitative multiplexed plasma proteomics analysis on immune complex disease MRL‐lpr mice

Proteomics (Weinheim), 2022-10, Vol.22 (19-20), p.e2100242-n/a

2022

Volltextzugriff (PDF)

1 – 25 von 59

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(47)

Publikationsform

Sprache

Englisch
(59)

Erscheinungsjahr

n.n

Thema

Science & Technology
(39)
Life Sciences & Biomedicine
(33)
Humans
(25)
Male
(13)
Adult
(11)
Female
(10)
Covid-19 - Prevention & Control
(9)
Pathology
(9)
Sars-Cov-2
(9)
Social Sciences
(9)
Antibodies
(8)
Bnt162 Vaccine
(8)
Covid-19
(8)
Covid-19 Vaccines
(7)
Middle Aged
(7)
Antibodies, Neutralizing
(6)
Severe Acute Respiratory Syndrome Coronavirus 2
(6)
Surgery
(6)
Adolescent
(5)
Antibodies, Viral
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination

Cross‐Reactive Antibody Responses to Coronaviruses Elicited by SARS‐CoV‐2 Infection or Vaccination

Immunogenicity against wild-type and Omicron SARS-CoV-2 after a third dose of inactivated COVID-19 vaccine in healthy adolescents

Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine

Author Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents

Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection

Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents

Durability for 12 months of antibody response to a booster dose of monovalent BNT162b2 in adults who had initially received 2 doses of inactivated vaccine

Natural Reassortment of Eurasian Avian-like Swine H1N1 and Avian H9N2 Influenza Viruses in Pigs, China

Slow Waning of Antibodies Following BNT162b2 as a Third Dose in Adults Who Had Previously Received 2 Doses of Inactivated Vaccine

Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection

Superior antibody and membrane protein-specific T-cell responses to CoronaVac by intradermal versus intramuscular routes in adolescents

Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after third-dose BNT162b2 in adolescents

Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial

Slow waning of antibodies following a third dose of BNT162b2 in adults who had previously received two doses of inactivated vaccine

Immunogenicity of a third dose of BNT162b2 to ancestral SARS-CoV-2 & Omicron variant in adults who received two doses of inactivated vaccine

Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination

Neutralizing antibodies against the SARS-CoV-2 Omicron BA.1 variant following homologous and heterologous CoronaVac or BNT162b2 vaccination

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

Security analysts and capital market anomalies

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

Magnetic augmentation through multi-gradient coupling enables direct and programmable profiling of circulating biomarkers

Replicating and Digesting Anomalies in the Chinese A-Share Market

Randomized, placebo-controlled, double-blind, pilot trial to investigate safety and efficacy of Cerebrolysin in patients with aneurysmal subarachnoid hemorrhage

Triple‐threat quantitative multiplexed plasma proteomics analysis on immune complex disease MRL‐lpr mice

Suchergebnisse filtern